Welcome to MOLOGEN AG

Our research - for you. That means, we conduct research to develop highly effective drugs with few side effects and excellent tolerability. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

Biotechnology company MOLOGEN is today publishing its annual results for fiscal year 2014. The company achieved significant progress in the ongoing development of its cancer immunotherapies. In the past financial year, two studies were started with the lead product candidate MGN1703: the IMPALA pivotal study in the indication colorectal cancer... [more]

Today, the executive board of MOLOGEN AG (ISIN DE0006637200/WKN 663720) resolved, with the approval of the supervisory board, to increase the share capital of the company against contributions in cash and with indirect subscription rights for existing shareholders by partial utilization of the authorized capital pursuant to section 4 para. 3 of... [more]

Annual Report 2014
Download PDF (0,4 MB)

Capital Increase 2015

Please click here for further information.